European Journal of Molecular & Clinical Medicine

Abstract

COPD is a growing global epidemic and it is estimated to kill around 3 million people every
year. It is currently the 4th largest killer disease in the world and expected to climb to 3rd
position by the year 2030. WHO has estimated that 600 million people worldwide have
COPD. It affects around 5-10% of population over the age of 40 years but still there is wide
variations in the prevalence between countries. Patients underwent Spirometric analysis and
those with post bronchodilator FEV1 < 40% are asked for willingness to participate in the
study. Those who are willing to participate are screened for inclusion into the study. Informed
Consent was obtained from all the patients. GOLD criteria revealed that majority of the
patients in our study i.e.27(45%) were of Grade 1 followed by 22(36.7%) were from Grade 2,
10(16.7%) from Grade 3 and 1(1.7%) were of Grade 4.